The UKI NETS 2024 Annual Conference will continue to support our NET community to promote collaborations, education and advancement of practice in the field of neuroendocrine neoplasms (NENs).
For future UKI NETS conferences
This is the leading NET conference in UK and Ireland and we have sponsorship packages available to offer you to make the most of your conference experience.
If you are interested in any of our sponsorship and exhibition opportunities for 2024, please email [email protected]
Meeting Partners
Novartis
Novartis purpose is to reimagine medicine to improve and extend people’s lives. The Radioligand Therapy team at Novartis focus on the development of products for targeted radioligand therapy and precision radioligand imaging.
Ipsen UK Limited
Ipsen U.K. and Ireland is a core part of Ipsen’s global biopharmaceutical business and is driven by the belief that patients don’t have time to wait. Our licensed medicines and R&D are all focused on improving quality of life and relieving suffering, hoping to bring real value to the healthcare community along every step of the treatment pathway. We push ourselves to address the most complex and difficult issues facing people’s health to deliver better outcomes. This purpose driven approach ensures we deliver real impact, in a sustainable way, for patients and society. Ipsen works across a diverse oncology portfolio in the U.K. and Ireland, which includes prostate cancer, neuroendocrine tumours, renal cell carcinoma, hepatocellular carcinoma and differentiated thyroid cancers.
We invite you to join us at our symposium, taking place on Monday 2 December 2024 at 13:15–14:00 GMT (in Calon Suite 1). Join our expert faculty, Professor Martyn Caplin, Professor Philippe Ruszniewski, Professor Marianne Pavel and Wendy Martin, who will discuss the current and future management strategies for NETs, reflect on the significant milestones achieved over the past decade and future directions in NETs management.
The promotional symposium has been commissioned by Ipsen and is intended for UK HCPs. Company products will be discussed at this meeting.
Ipsen has sponsored the UKI NETS 22nd Annual conference and in return has received an exhibition stand and a satellite symposium, which have been developed and funded by Ipsen. Ipsen has not had any involvement in the creation of the conference agenda and selection of speakers.
ALLSC-UK-001730 | November 2024
Esteve
ESTEVE is a global pharmaceutical company with headquarters in Barcelona. Its purpose is to improve people’s lives and, since its founding in 1929, its focus has been providing solutions for unmet medical needs.
ESTEVE has an important presence in Europe thanks to its affiliates in Spain, Portugal, Germany, France, UK and Italy, and is a leading European contract manufacturing organization (CMO) with production centers dedicated to the development and production of active pharmaceutical ingredients for third parties, in Spain, Mexico and China
The ESTEVE industry symposium will take place on Monday 2 December at 08:00 – 08:45. More details will follow shortly.
ITM
ITM, a leading radiopharmaceutical biotech company, is dedicated to providing a new generation of radiomolecular precision therapeutics and diagnostics for hard-to-treat tumors. We aim to meet the needs of cancer patients, clinicians and our partners through excellence in development, production and global supply. With improved patient benefit as the driving principle for all we do, ITM advances a broad precision oncology pipeline, including two phase III studies, combining the company’s high-quality radioisotopes with a range of targeting molecules. By leveraging our nearly two decades of pioneering radiopharma expertise, central industry position and established global network, ITM strives to provide patients with more effective targeted treatment to improve clinical outcome and quality of life. www.itm-radiopharma.com
SERB Pharmaceuticals
SERB Pharmaceuticals represents the combination of SERB, BTG Specialty Pharmaceuticals and Veriton Pharma Ltd to form a new, growing specialty pharmaceutical company focused on critical care and rare diseases.
We make treating complex and life-threatening conditions possible; supporting clinicians, healthcare systems and governments while offering hope to patients and their families.
As a fully integrated company, we have the experience and capabilities to acquire, develop, and manufacture our medicines to the highest standards, and make them available worldwide through our secure supply chain.
Improving patients’ quality of life and offering hope is what motivates and inspires us.
Patient Support Groups
UKI NETS would like to extend its thanks to both AMEND and NCUK for their continued support of the Annual Conference.
